Cargando…

Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma in situ and minimally invasive adenocarcinoma of lung

OBJECTIVES: According to the IASLC/ATS/ERS 2011 classification, there are two new conceptions of lung adenocarcinoma, adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), which are very early stages of lung adenocarcinoma. This study aimed to analyze clinical features of AIS and MI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Renke, He, Zhengfu, Lou, Ying, Jiang, Hanliang, Wu, Yuhui, Liu, Zhen, Pan, Hongming, Han, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716692/ https://www.ncbi.nlm.nih.gov/pubmed/29228652 http://dx.doi.org/10.18632/oncotarget.22082

Ejemplares similares

Can computed tomography differentiate adenocarcinoma in situ from minimally invasive adenocarcinoma?
por: Yoshida, Mitsuteru, et al.
Publicado: (2021)

CT Texture Analysis for Differentiating Bronchiolar Adenoma, Adenocarcinoma In Situ, and Minimally Invasive Adenocarcinoma of the Lung
por: Sun, Jinju, et al.
Publicado: (2021)

Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma
por: Song, Zhengbo, et al.
Publicado: (2016)

Clinicopathological characteristics correlated with programmed cell death-ligand 1 expression in advanced lung adenocarcinoma
por: Gao, Hengxing, et al.
Publicado: (2023)

Adenocarcinoma in situ and minimally invasive adenocarcinoma in lungs of smokers: image feature differences from those in lungs of non-smokers
por: Sugawara, Haruto, et al.
Publicado: (2021)

Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma
por: Su, Hang, et al.
Publicado: (2021)

The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma
por: Wu, Shafei, et al.
Publicado: (2017)

Development of a novel nomogram-based model incorporating 3D radiomic signatures and lung CT radiological features for differentiating invasive adenocarcinoma from adenocarcinoma in situ and minimally invasive adenocarcinoma
por: Ren, He, et al.
Publicado: (2022)

Elucidating Genomic Characteristics of Lung Cancer Progression from In Situ to Invasive Adenocarcinoma
por: Vinayanuwattikun, Chanida, et al.
Publicado: (2016)

Coexistence of atypical adenomatous hyperplasia, minimally invasive adenocarcinoma and invasive adenocarcinoma: Gene mutation analysis
por: Song, Junya, et al.
Publicado: (2021)

Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers
por: Liang, Sheng-Kai, et al.
Publicado: (2021)

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2014)

Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma
por: Xu, Cheng, et al.
Publicado: (2018)

Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients
por: Chen, Jun, et al.
Publicado: (2017)

Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma
por: Zhang, Zhenfa, et al.
Publicado: (2013)

Analysis of CT morphologic features and attenuation for differentiating among transient lesions, atypical adenomatous hyperplasia, adenocarcinoma in situ, minimally invasive and invasive adenocarcinoma presenting as pure ground-glass nodules
por: Qi, Lin, et al.
Publicado: (2019)

Development and Validation a Nomogram Incorporating CT Radiomics Signatures and Radiological Features for Differentiating Invasive Adenocarcinoma From Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma Presenting as Ground-Glass Nodules Measuring 5-10mm in Diameter
por: Shi, Lili, et al.
Publicado: (2021)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Mucinous adenocarcinoma of the renal pelvis with adenocarcinoma in situ of the ureter
por: Raphael, Vandana, et al.
Publicado: (2011)

Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
por: Liu, Drolaiz H. W., et al.
Publicado: (2023)

Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment
por: Hoshimoto, Aitoshi, et al.
Publicado: (2023)

Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients
por: Wang, Shuo, et al.
Publicado: (2021)

Quantitative CT Analysis of Pulmonary Ground-Glass Opacity Nodules for the Distinction of Invasive Adenocarcinoma from Pre-Invasive or Minimally Invasive Adenocarcinoma
por: Son, Ji Ye, et al.
Publicado: (2014)

Comparison of Comprehensive Morphological and Radiomics Features of Subsolid Pulmonary Nodules to Distinguish Minimally Invasive Adenocarcinomas and Invasive Adenocarcinomas in CT Scan
por: Qiu, Lu, et al.
Publicado: (2022)

Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma
por: Pal, Krishnendu, et al.
Publicado: (2022)

Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma
por: Pan, Hongming, et al.
Publicado: (2021)

POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma
por: Rahn, Sascha, et al.
Publicado: (2019)

Infiltration of tumor‐associated macrophages is involved in tumor programmed death‐ligand 1 expression in early lung adenocarcinoma
por: Shima, Toshiyuki, et al.
Publicado: (2020)

Ezrin Modulates the Cell Surface Expression of Programmed Cell Death Ligand-1 in Human Cervical Adenocarcinoma Cells
por: Tanaka, Chihiro, et al.
Publicado: (2021)

Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples
por: Muggilli, Michael, et al.
Publicado: (2021)

Programmed Death Ligand-1 Testing in Adenocarcinoma Lung: A Comparative Study of Cell Block versus Biopsy
por: Shukla, Saumya, et al.
Publicado: (2023)

Exosome-Derived miR-486-5p Regulates Cell Cycle, Proliferation and Metastasis in Lung Adenocarcinoma via Targeting NEK2
por: Hu, Huihui, et al.
Publicado: (2020)

Evaluation of dynamic image progression of minimally invasive and preinvasive lung adenocarcinomas
por: Chen, Tianxiang, et al.
Publicado: (2021)

Survival After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma
por: Topal, Halit, et al.
Publicado: (2022)

Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature
por: Sheng, Jin, et al.
Publicado: (2023)

A Non-invasive Method to Diagnose Lung Adenocarcinoma
por: Yan, Mengmeng, et al.
Publicado: (2020)

Exploring the Effect of Differentially Expressed Long Non-coding RNAs Driven by Copy Number Variation on Competing Endogenous RNA Network by Mining Lung Adenocarcinoma Data
por: Hu, Huihui, et al.
Publicado: (2021)

Five cases of BRAF V600E-mutant lung adenocarcinoma with high expression of programmed death ligand 1
por: Katano, Takuma, et al.
Publicado: (2020)

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
por: Kang, Minsu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lisrhb45mqjouda5jesefv6n8b